ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lonza has signed a deal to provide pharmaceutical services to biotech companies in the portfolio of Israel Biotech Fund (IBF), a venture capital firm. Lonza will develop and manufacture both biologics and small molecules. It will also help IBF in its review of potential investment targets. In turn, IBF will provide Lonza with access to Israel’s biotech industry. Lonza has a similar pact with the European venture firms Forbion and BioGeneration Ventures.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X